Drug intelligence / Profile preview

VCE-009.1

Development stage: Preclinical
Lead developer: Emerald Health Biotechnology España
Modality: Small Molecules
Administration: Oral

Overview

VCE-009.1 is a small molecule positive allosteric modulator (PAM) of the cannabinoid receptor 1 (CB1R) currently in preclinical development by Emerald Health Biotechnology España (VivaCell Biotechnology Spain). As a PAM, VCE-009.1 enhances the activity of the receptor in response to endogenous ligands rather than activating it directly. This approach aims to provide therapeutic benefits for pain management while minimizing the psychotropic side effects often associated with direct CB1R agonists.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on VCE-009.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCE-009.1.

Explore the full profile